- Home
- TC vs ZVSA Comparison
TC vs ZVSA Comparison
Compare TC & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- ZVSA
- Stock Information
- Founded
- TC 2010
- ZVSA 2014
- Country
- TC China
- ZVSA United States
- Employees
- TC N/A
- ZVSA N/A
- Industry
- TC Business Services
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- ZVSA Health Care
- Exchange
- TC Nasdaq
- ZVSA Nasdaq
- Market Cap
- TC 1.9M
- ZVSA 1.5M
- IPO Year
- TC 2018
- ZVSA N/A
- Fundamental
- Price
- TC $1.00
- ZVSA $1.42
- Analyst Decision
- TC
- ZVSA Strong Buy
- Analyst Count
- TC 0
- ZVSA 1
- Target Price
- TC N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- TC 178.2K
- ZVSA 2.2M
- Earning Date
- TC 08-30-2024
- ZVSA 11-14-2024
- Dividend Yield
- TC N/A
- ZVSA N/A
- EPS Growth
- TC N/A
- ZVSA N/A
- EPS
- TC N/A
- ZVSA N/A
- Revenue
- TC $14,107,804.00
- ZVSA N/A
- Revenue This Year
- TC N/A
- ZVSA N/A
- Revenue Next Year
- TC N/A
- ZVSA N/A
- P/E Ratio
- TC N/A
- ZVSA N/A
- Revenue Growth
- TC N/A
- ZVSA N/A
- 52 Week Low
- TC $0.75
- ZVSA $0.98
- 52 Week High
- TC $4.30
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- TC 49.11
- ZVSA 57.25
- Support Level
- TC $0.88
- ZVSA $1.31
- Resistance Level
- TC $1.03
- ZVSA $1.95
- Average True Range (ATR)
- TC 0.10
- ZVSA 0.19
- MACD
- TC -0.01
- ZVSA 0.04
- Stochastic Oscillator
- TC 32.43
- ZVSA 44.21
About TC TuanChe Limited
TuanChe Ltd is an omnichannel automotive marketplace in China. The company operates in one operating segment of providing auto shows, special promotion events services, and virtual dealership, online marketing services, and others. It organizes auto shows, which aim at facilitating transactions between consumers and auto dealers that include auto dealers, automakers, and automotive service providers. It provides services through its online platform and offline events.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.